A retrospective case series of ovarian stimulation with follitropin delta in a mixed regimen with HP-hMG: An interim analysis of clinical outcomes
05 Dec 2022
Studies have shown that controlled ovarian stimulation (COS) supplementation with human chorionic gonadotropin (hCG)-driven luteinising hormone activity such as highly purified human menopausal gonadotropin (HP-hMG) (Menopur®) resulted in a significantly higher proportion of top-quality embryos and numbers of good-quality blastocysts compared with recombinant follicle-stimulating hormone (rFSH) alone. Regimens that combine FSH and hMG are often referred to as ‘mixed protocols’ and have been widely used for ovarian stimulation in the past decade. This single-centre, retrospective case series study aims to assess the efficacy of COS with follitropin delta in a mixed protocol regimen with HP-hMG in terms of the number of top-quality embryos and clinical pregnancy rate among Malaysian patients in a reproductive medicine clinic.